(Q46045006)

English

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

scientific article published in June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

0 references

author name string

Dar-In Tai

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

Shi-Ming Lin

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

I-Shyan Sheen

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

Chia-Ming Chu

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

Deng-Yn Lin

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

language of work or name

0 references

publication date

1 June 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

49

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

1859-1867

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Serum aminotransferase activity and mortality risk in a United States community.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

The clinical significance of persistently normal ALT in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Long-term outcome of chronic hepatitis B based on histological grade and stage.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

PGC-1alpha controls hepatitis B virus through nutritional signals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

21 January 2018

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22878

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.22878

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19378345

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46045006&oldid=2089343066"